CN112601759A - 嵌合生长因子受体 - Google Patents

嵌合生长因子受体 Download PDF

Info

Publication number
CN112601759A
CN112601759A CN201980055314.2A CN201980055314A CN112601759A CN 112601759 A CN112601759 A CN 112601759A CN 201980055314 A CN201980055314 A CN 201980055314A CN 112601759 A CN112601759 A CN 112601759A
Authority
CN
China
Prior art keywords
cell
domain
cells
receptor
tpor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980055314.2A
Other languages
English (en)
Chinese (zh)
Inventor
N·K·普莱斯
J·S·布里奇曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
British Research Biology Uk Ltd
Original Assignee
British Research Biology Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63042840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN112601759(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by British Research Biology Uk Ltd filed Critical British Research Biology Uk Ltd
Publication of CN112601759A publication Critical patent/CN112601759A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN201980055314.2A 2018-06-21 2019-06-21 嵌合生长因子受体 Pending CN112601759A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1810181.6 2018-06-21
GBGB1810181.6A GB201810181D0 (en) 2018-06-21 2018-06-21 Cells expressing chimeric recominant growth factor receptors
PCT/GB2019/051745 WO2019243835A1 (en) 2018-06-21 2019-06-21 Chimeric growth factor receptors

Publications (1)

Publication Number Publication Date
CN112601759A true CN112601759A (zh) 2021-04-02

Family

ID=63042840

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980055314.2A Pending CN112601759A (zh) 2018-06-21 2019-06-21 嵌合生长因子受体

Country Status (19)

Country Link
US (1) US20210205365A1 (https=)
EP (1) EP3810646A1 (https=)
JP (2) JP2021527425A (https=)
KR (1) KR20210022690A (https=)
CN (1) CN112601759A (https=)
AU (1) AU2019289202B2 (https=)
BR (1) BR112020026233A2 (https=)
CA (1) CA3104079A1 (https=)
CL (1) CL2020003319A1 (https=)
CO (1) CO2020016052A2 (https=)
CR (1) CR20200624A (https=)
EA (1) EA202190100A1 (https=)
EC (1) ECSP20082338A (https=)
GB (1) GB201810181D0 (https=)
IL (1) IL279469A (https=)
MX (1) MX2020014257A (https=)
PH (1) PH12020500678A1 (https=)
SG (1) SG11202012726QA (https=)
WO (1) WO2019243835A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
GB201900858D0 (en) * 2019-01-22 2019-03-13 Price Nicola Kaye Receptors providing targeted costimulation for adoptive cell therapy
BR112022011795A2 (pt) 2019-12-20 2022-08-30 Instil Bio Uk Ltd Métodos para preparar e isolar uma população terapêutica de linfócitos e para tratar câncer em um indivíduo, população terapêutica de linfócitos, bolsa criopreservada, recipiente flexível, e, sistema para extração de linfócitos
EP4110355A1 (en) * 2020-02-24 2023-01-04 The United States of America, as represented by the Secretary, Department of Health and Human Services Nk cells or t cells expressing hematopoietic growth factor receptors and use for treating cancer
EP4263807A2 (en) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes
EP4262828A1 (en) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Tumor infiltrating lymphocytes and anti-cd47 therapeutics
JP2023554425A (ja) 2020-12-18 2023-12-27 インスティル バイオ （ユーケイ） リミテッド 腫瘍浸潤リンパ球の処理
US20250288666A1 (en) 2021-07-14 2025-09-18 Synthekine, Inc. Methods and compositions for use in cell therapy of neoplastic disease
WO2025076134A1 (en) * 2023-10-03 2025-04-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nk cells or t cells expressing chimeric hematopoietic growth factor receptors and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140047572A1 (en) * 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
WO2017103596A1 (en) * 2015-12-15 2017-06-22 Cellular Therapeutics Ltd Cells expressing recombinant growth factor receptors
CN107106665A (zh) * 2014-06-06 2017-08-29 纪念斯隆-凯特琳癌症中心 靶向间皮素的嵌合抗原受体及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69941126D1 (de) * 1998-09-23 2009-08-27 Zymogenetics Inc Cytokinerezeptor zalpha11
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
US20030096339A1 (en) * 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
WO2018175476A1 (en) * 2017-03-20 2018-09-27 Baylor College Of Medicine Transgenic c-mpl provides ligand-dependent co-stimulation and cytokine signals to tcr-engineered cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140047572A1 (en) * 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
CN107106665A (zh) * 2014-06-06 2017-08-29 纪念斯隆-凯特琳癌症中心 靶向间皮素的嵌合抗原受体及其用途
WO2017103596A1 (en) * 2015-12-15 2017-06-22 Cellular Therapeutics Ltd Cells expressing recombinant growth factor receptors
EP3390436A1 (en) * 2015-12-15 2018-10-24 Immetacyte Limited Cells expressing recombinant growth factor receptors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AUSTIN L. GURNEY等: "Distinct regions of c-Mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and Shc phosphorylation", PROC. NATL. ACAD. SCI., vol. 92, 30 June 1995 (1995-06-30), pages 1 - 3 *
GENBANK: "thrombopoietin receptor precursor [Homo sapiens]", GENBANK, 10 April 2018 (2018-04-10), pages 005364 *
MASAHIRO KAWAHARA等: "Engineering of mammalian cell membrane proteins", BIOTECHNOLOGY AND BIOPROCESS ENGINEERING, vol. 1, 13 June 2012 (2012-06-13), pages 411 - 417, XP055267820, DOI: 10.1016/j.coche.2012.05.002 *
魏枫;任秀宝;: "肿瘤过继免疫细胞治疗靶抗原选择的新视野", 中国肿瘤生物治疗杂志, no. 02, 20 April 2015 (2015-04-20), pages 191 - 196 *

Also Published As

Publication number Publication date
AU2019289202A1 (en) 2021-01-14
JP2024156656A (ja) 2024-11-06
CR20200624A (es) 2021-06-24
CL2020003319A1 (es) 2021-07-09
CA3104079A1 (en) 2019-12-26
US20210205365A1 (en) 2021-07-08
AU2019289202B2 (en) 2024-10-31
MX2020014257A (es) 2021-07-21
JP2021527425A (ja) 2021-10-14
SG11202012726QA (en) 2021-01-28
CO2020016052A2 (es) 2021-01-29
EA202190100A1 (ru) 2021-04-23
EP3810646A1 (en) 2021-04-28
WO2019243835A1 (en) 2019-12-26
KR20210022690A (ko) 2021-03-03
IL279469A (en) 2021-01-31
BR112020026233A2 (pt) 2021-04-20
PH12020500678A1 (en) 2021-07-12
ECSP20082338A (es) 2021-02-26
GB201810181D0 (en) 2018-08-08

Similar Documents

Publication Publication Date Title
US12116564B2 (en) Cells expressing recombinant growth factor receptors
AU2019289202B2 (en) Chimeric growth factor receptors
JP7460675B2 (ja) Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用
JP7475088B2 (ja) ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞
EP3680338A1 (en) Genetically engineered t cell and application thereof
US20180104337A1 (en) Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
CN107849112A (zh) 嵌合抗原受体(car)、组合物及其使用方法
KR20240115908A (ko) 면역 기능 제어 인자를 발현하는 면역 담당 세포 및 발현 벡터
RS63601B1 (sr) Vektor ekspresije car i t ćelije koje eksprimiraju car
JP2018042531A (ja) キメラ抗原受容体
JP7766674B2 (ja) 二重ｃａｒ－ｔ細胞
WO2021202581A1 (en) Engineered immune cells for adoptive cell therapy
RU2839662C1 (ru) Т-клетки с двумя химерными антигенными рецепторами car
US12618048B2 (en) Dual CAR-T cells
WO2025075075A1 (ja) キメラ抗原受容体、ポリヌクレオチド、ベクター、細胞、細胞の製造方法及び医薬組成物
CN119039461A (zh) 一种新型嵌合受体及其应用
CN110938641A (zh) 靶向april的嵌合抗原受体及其用途
Sukumar Mechanisms of Rejection of High Grade B Cell Lymphoma in Mice
JP2019154347A (ja) キメラ抗原受容体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210402

WD01 Invention patent application deemed withdrawn after publication